drugset / Trial / NCT00823836
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
To investigate the efficacy and the safety of ropinirole PR/XR tablets to ropinirole immediate release (IR) tablets with advanced Parkinson's disease in conjunction with L-dopa in a double-blind, parallel group comparison study.
Timeline
- Start
- 2009-03
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropinirole | Small molecule | 0.75 mg | — |
| Subject | Ropinirole | Small molecule | 2 mg | — |
| Subject | Ropinirole | Small molecule | 15 mg | — |